Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maurice Dickins

Showing results (11-20 of 25) with videos related to

Pageof 3
Sort By:
Drug Metabolism and Drug Interactions|May 20, 2003
Molecular modelling of CYP2B6 based on homology with the CYP2C5 crystal structure: analysis of enzyme-substrate interactionsDavid F V Lewis, Brian G Lake, Maurice Dickins, et al.
Drug Metabolism and Drug Interactions|February 11, 2004
Investigation of enzyme selectivity in the human CYP2C subfamily: homology modelling of CYP2C8, CYP2C9 and CYP2C19 from the CYP2C5 crystallographic templateDavid F V Lewis, Maurice Dickins, Brian G Lake, et al.
Drug Metabolism and Drug Interactions|December 20, 2003
A molecular model of CYP2D6 constructed by homology with the CYP2C5 crystallographic template: investigation of enzyme-substrate interactionsDavid F V Lewis, Maurice Dickins, Brian G Lake, et al.
Clinical Pharmacology and Therapeutics|April 12, 2018
Risk-Benefit Assessment of Ethinylestradiol Using a Physiologically Based Pharmacokinetic Modeling ApproachUdoamaka Ezuruike, Helen Humphries, Maurice Dickins, et al.
British Journal of Clinical Pharmacology|May 7, 2011
Effects of the moderate CYP3A4 inhibitor, fluconazole, on the pharmacokinetics of fesoterodine in healthy subjectsBimal Malhotra, Maurice Dickins, Christine Alvey, et al.
Drug Metabolism Letters|March 6, 2010
An evaluation of ondansetron binding interactions with human cytochrome P450 enzymes CYP3A4 and CYP2D6David F V Lewis, Yuko Ito, Peter J Eddershaw, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|November 15, 2011
The evolution of the OATP hepatic uptake transport protein family in DMPK sciences: from obscure liver transporters to key determinants of hepatobiliary clearanceKatherine S Fenner, Hannah M Jones, Mohammed Ullah, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 2, 2009
Comparison of different algorithms for predicting clinical drug-drug interactions, based on the use of CYP3A4 in vitro data: predictions of compounds as precipitants of interactionOdette A Fahmi, Susan Hurst, David Plowchalk, et al.
British Journal of Clinical Pharmacology|February 19, 2008
Application of CYP3A4 in vitro data to predict clinical drug-drug interactions; predictions of compounds as objects of interactionKuresh A Youdim, Aref Zayed, Maurice Dickins, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|March 27, 2007
The time to move cytochrome p450 induction into mainstream pharmacology is long overdueDennis A Smith, Maurice Dickins, Odette A Fahmi, et al.
Pageof 3

Showing results (11-20 of 25) with videos related to

Sort By:
Pageof 3
Drug Metabolism and Drug Interactions|May 20, 2003
Molecular modelling of CYP2B6 based on homology with the CYP2C5 crystal structure: analysis of enzyme-substrate interactionsDavid F V Lewis, Brian G Lake, Maurice Dickins, et al.
Drug Metabolism and Drug Interactions|February 11, 2004
Investigation of enzyme selectivity in the human CYP2C subfamily: homology modelling of CYP2C8, CYP2C9 and CYP2C19 from the CYP2C5 crystallographic templateDavid F V Lewis, Maurice Dickins, Brian G Lake, et al.
Drug Metabolism and Drug Interactions|December 20, 2003
A molecular model of CYP2D6 constructed by homology with the CYP2C5 crystallographic template: investigation of enzyme-substrate interactionsDavid F V Lewis, Maurice Dickins, Brian G Lake, et al.
Clinical Pharmacology and Therapeutics|April 12, 2018
Risk-Benefit Assessment of Ethinylestradiol Using a Physiologically Based Pharmacokinetic Modeling ApproachUdoamaka Ezuruike, Helen Humphries, Maurice Dickins, et al.
British Journal of Clinical Pharmacology|May 7, 2011
Effects of the moderate CYP3A4 inhibitor, fluconazole, on the pharmacokinetics of fesoterodine in healthy subjectsBimal Malhotra, Maurice Dickins, Christine Alvey, et al.
Drug Metabolism Letters|March 6, 2010
An evaluation of ondansetron binding interactions with human cytochrome P450 enzymes CYP3A4 and CYP2D6David F V Lewis, Yuko Ito, Peter J Eddershaw, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|November 15, 2011
The evolution of the OATP hepatic uptake transport protein family in DMPK sciences: from obscure liver transporters to key determinants of hepatobiliary clearanceKatherine S Fenner, Hannah M Jones, Mohammed Ullah, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 2, 2009
Comparison of different algorithms for predicting clinical drug-drug interactions, based on the use of CYP3A4 in vitro data: predictions of compounds as precipitants of interactionOdette A Fahmi, Susan Hurst, David Plowchalk, et al.
British Journal of Clinical Pharmacology|February 19, 2008
Application of CYP3A4 in vitro data to predict clinical drug-drug interactions; predictions of compounds as objects of interactionKuresh A Youdim, Aref Zayed, Maurice Dickins, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|March 27, 2007
The time to move cytochrome p450 induction into mainstream pharmacology is long overdueDennis A Smith, Maurice Dickins, Odette A Fahmi, et al.
Pageof 3